| High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array YC Tung, AY Hsiao, SG Allen, Y Torisawa, M Ho, S Takayama Analyst 136 (3), 473-478, 2011 | 1155 | 2011 |
| Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors JAA Gubbels, J Belisle, M Onda, C Rancourt, M Migneault, M Ho, TK Bera, ... Molecular cancer 5, 1-15, 2006 | 484 | 2006 |
| Mesothelin targeted cancer immunotherapy R Hassan, M Ho European journal of cancer 44 (1), 46-53, 2008 | 402 | 2008 |
| Glypican-3: a new target for cancer immunotherapy M Ho, H Kim European journal of cancer 47 (3), 333-338, 2011 | 278 | 2011 |
| Isolation of anti-CD22 Fv with high affinity by Fv display on human cells M Ho, S Nagata, I Pastan Proceedings of the National Academy of Sciences 103 (25), 9637-9642, 2006 | 255 | 2006 |
| Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update A Gauthier, M Ho Hepatology Research 43 (2), 147-154, 2013 | 254 | 2013 |
| Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma M Feng, W Gao, R Wang, W Chen, YG Man, WD Figg, XW Wang, ... Proceedings of the National Academy of Sciences 110 (12), E1083-E1091, 2013 | 210 | 2013 |
| A binding domain on mesothelin for CA125/MUC16 O Kaneko, L Gong, J Zhang, JK Hansen, R Hassan, B Lee, M Ho Journal of Biological Chemistry 284 (6), 3739-3749, 2009 | 205 | 2009 |
| A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune … DH Sterman, A Recio, RG Carroll, CT Gillespie, A Haas, A Vachani, ... Clinical Cancer Research 13 (15), 4456-4466, 2007 | 198 | 2007 |
| Mesothelin expression in human lung cancer M Ho, TK Bera, MC Willingham, M Onda, R Hassan, D FitzGerald, ... Clinical cancer research 13 (5), 1571-1575, 2007 | 189 | 2007 |
| Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients M Ho, R Hassan, J Zhang, Q Wang, M Onda, T Bera, I Pastan Clinical Cancer Research 11 (10), 3814-3820, 2005 | 183 | 2005 |
| Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy W Gao, H Kim, M Feng, Y Phung, CP Xavier, JS Rubin, M Ho Hepatology 60 (2), 576-587, 2014 | 172 | 2014 |
| New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells X Du, M Ho, I Pastan Journal of immunotherapy 30 (6), 607-613, 2007 | 165 | 2007 |
| In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin M Ho, RJ Kreitman, M Onda, I Pastan Journal of Biological Chemistry 280 (1), 607-617, 2005 | 155 | 2005 |
| The role of mesothelin in tumor progression and targeted therapy Z Tang, M Qian, M Ho Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents) 13 (2), 276-280, 2013 | 152 | 2013 |
| Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis W Gao, Z Tang, YF Zhang, M Feng, M Qian, DS Dimitrov, M Ho Nature communications 6 (1), 6536, 2015 | 151 | 2015 |
| Glypican-3 antibodies: a new therapeutic target for liver cancer M Feng, M Ho FEBS letters 588 (2), 377-382, 2014 | 146 | 2014 |
| Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice D Li, N Li, YF Zhang, H Fu, M Feng, D Schneider, L Su, X Wu, J Zhou, ... Gastroenterology 158 (8), 2250-2265. e20, 2020 | 137 | 2020 |
| Glypicans as cancer therapeutic targets N Li, W Gao, YF Zhang, M Ho Trends in cancer 4 (11), 741-754, 2018 | 136 | 2018 |
| Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma M Onda, S Nagata, M Ho, TK Bera, R Hassan, RH Alexander, I Pastan Clinical cancer research 12 (14), 4225-4231, 2006 | 132 | 2006 |
Mingqian Feng, Ph.DNational Institutes of HealthEmail yang diverifikasi di mail.nih.gov